Giuliana Vallanti

Giuliana Vallanti is VP, Development and Global Gene Therapy R&D.

She joined AGC bio, former MolMed, in 2005 and worked with growing responsibilities in Development  and Quality Control units, contributing to the development of processes and assays in cell and  gene therapy field. She has strong experiences in the development and industrialization of  cell therapy programs in allogenic and autologous setting with different cell types (NK, T cells, HSC, MCS) unmanipulated, gene edited and transduced with lentiviral and retroviral vectors. She worked on the development of GMP processes for large scale vectors production (AAV, LVV, RVV)  and purification in close systems from clinical trials to market approval.

She holds a degree in Biology and a Ph.D. in biochemical and pharmacological methods with a study on Lentiviral Vector for gene therapy anti HIV-1.